ALFA Finder
India's fastest NSE & BSE filing alerts on Telegram, filtered to the stocks you hold
Telegram alerts
alfafinder.com →
ALFA Filings
Every announcement, straight from the exchange
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
Announcement type
Time
80 announcements with these filters
Aurobindo Pharma Ltd reported revenue from operations of ₹9,150 Cr (+16.3% YoY) and net profit of ₹1,032 Cr (+25.2% YoY) for Q1 FY27.
Aurobindo Pharma dispatched letters to shareholders without registered email IDs. These letters provide a web link to the Integrated Annual Report 2025-26.
Aurobindo Pharma has submitted its Business Responsibility & Sustainability Report for the financial year 2025-26 to the stock exchanges.
Aurobindo Pharma Limited has submitted its Integrated Annual Report for FY 2025-26, alongside the notice for its 39th Annual General Meeting.
Aurobindo Pharma Limited has scheduled its 39th Annual General Meeting for August 27, 2026. The company also announced a closure of its Share Transfer Books for the AGM.
Aurobindo Pharma has scheduled a Board Meeting for August 5, 2026, to consider and approve its standalone and consolidated unaudited financial results for the quarter ended June 30, 2026.
Aurobindo Pharma signed a non-exclusive voluntary licensing agreement with MSD to manufacture and supply generic alimatravir for 129 low- and middle-income countries.
Aurobindo Pharma's subsidiary, Apitoria, will acquire an 80% stake in A1 Biochem Group for USD 13.6 Million to bolster its contract research and manufacturing capabilities.
Aurobindo Pharma's subsidiary, CuraTeQ Biologics, received ANVISA (Brazil) approval for its biosimilars manufacturing facility in Hyderabad. This approval enables supply to Brazilian and Latin American markets.
Aurobindo Pharma Ltd created a new wholly‑owned subsidiary, PT Auro Pharm Indonesia, acquiring it for Rs.10.58 Crore cash. The step‑down subsidiary completes the incorporation on July 9 2026.
Aurobindo Pharma disclosed its subsidiary PT Aurogen Pharma Indonesia has created PT Auro Pharm Indonesia, subscribing cash of IDR 20 billion. The unit will manufacture in Indonesia.
Aurobindo Pharma USA Inc. completed the acquisition of Lannett Company LLC for ₹2,185 Crore. The deal adds Lannett's assets to Aurobindo’s portfolio.
Aurobindo Pharma USA Inc completed the acquisition of Lannett Company, making it a wholly‑owned subsidiary. The deal expands the group's capabilities in essential medicines.
US FDA completed an inspection at Auroactive Pharma, a wholly owned subsidiary. The inspection resulted in two observations to be responded to.
Aurobindo Pharma completed the acquisition of a 26% stake in Swarnaaskshu Solar Power for Rs.0.52 Crore. The deal secures solar power under Telangana's captive policy.
Aurobindo Pharma acquired a 26% stake in Swarnaakshu Solar Power. The investment is valued at Rs.10.40 Crore.
US FDA classified Aurobindo's subsidiary facility as OAI after an inspection. The company states no immediate financial impact but faces regulatory scrutiny.
Aurobindo Pharma received final US FDA approval for Tofacitinib Tablets used in treating rheumatoid arthritis. The product will be manufactured by its subsidiary and launched immediately.
Aurobindo Pharma inaugurated TheraNym, its large-scale biologics manufacturing facility in Telangana. MSD has joined as the anchor customer, strengthening the company's global contract manufacturing footprint.
Aurobindo delivered record performance in FY26 with revenues at ₹33,653cr and 20.4% EBITDA margins. Strategy focuses on specialty injectables, biosimilars expansion, and backward integration via Pen-G/6-APA projects.
Aurobindo Pharma subsidiary's Unit-I facility received an 'official action indicated' (OAI) classification from the US FDA. The company maintains there is no financial impact.
Aurobindo Pharma's step-down subsidiary incorporated Arrow Pharma Production SAS in France. The new ₹1.11 Crore entity will expand generic formulation manufacturing operations.
Aurobindo Pharma appointed RPR & Associates and Ernst & Young LLP as secretarial and internal auditors. The board meeting also accepted MRR & Associates' resignation.
Aurobindo Pharma re-appointed Ernst & Young LLP as Internal Auditors for June 2026 to May 2027. The move ensures continuity in internal audit and governance processes.
Aurobindo Pharma appointed M/s. RPR & Associates as Secretarial Auditor for five years following M/s. MRR & Associates' resignation. The transition is due to proprietor health issues.
Aurobindo Pharma reported Q4FY26 revenue of ₹8,853 Cr (+5.6% YoY) and PAT of ₹921 Cr (+2.0% YoY). The firm focuses on biosimilars expansion via CuraTeQ and biologics CDMO through TheraNym.
Aurobindo Pharma reported Q4FY26 revenue of ₹8,853 Crore, a 5.6% YoY increase. Net profit rose 2.0% to ₹921 Crore, supported by strong European business growth.
Aurobindo Pharma Ltd reported revenue from operations of ₹8,853 Cr (+5.6% YoY) and net profit of ₹920.8 Cr (+2.0% YoY) for Q4 FY26.
Aurobindo Pharma reported consolidated annual revenue of ₹33,653.08 Crore and profit after tax of ₹3,502.97 Crore. The results show consistent performance across its global pharmaceutical operations.
Aurobindo Pharma subsidiary CuraTeQ received CDSCO marketing approval for Bevqolva, a bevacizumab biosimilar. The authorisation permits domestic manufacturing and marketing for metastatic colorectal cancer treatment.